For updates visit

Take Solutions ends with 27% premium

Monday, August 27, 2007

Take Solutions settled at Rs 926.50 on the BSE, a premium of 26.91% over the IPO price of Rs 730.

On BSE, 56.53 lakh shares of the scrip were traded. The stock had debuted at Rs 876, a premium of 20% over the IPO price. It had hit a high of Rs 943.30 and a low of Rs 839.15.

At the current price of Rs 926.50, the PE works out to 35.09, based on the year ended March 2007 EPS of 26.4.

The company had fixed the IPO price at the top end of the Rs 675-730 price band. The IPO had ended on 7 August 2007 with 57.97 times subscription.

The qualified institutional buyer (QIB) category was subscribed 75.58 times, the non-institutional investor category 100 times, and the retail investor category 23.33 times. The employee category was subscribed 1.05 times.

Take Solutions is an IT firm focussed on supply chain management and life sciences verticals. The objects of the IPO was to raise fresh capital that can be deployed in the acquisition of companies, businesses and products as well as to repay debt utilised in the acquisition of ClearOrbit Inc of US.

In June 2007, Take Solutions had acquired Texas based ClearOrbit, a supply chain execution and collaborative supply management solutions provider, for $20.6 million.

The company, along with its subsidiaries, has completed more than 2,500 software installations for over 250 customers ranging in size from multinational enterprises to medium- and smaller-sized companies, as on 31 March 2007.

It recently approved allotment of 9 lakh shares to Galleon International Master Fund SPC and Passport India Investments (Mauritius).

Take Solutions reported a net profit of Rs 31.71 crore on an operating revenue of Rs 182.16 crore in the year ended March 2007.

Posted by FR at 8:21 PM  

0 comments:

Post a Comment

IMPORTANT DISCLAIMER

Investment in equity shares has its own risks. Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that we consider reliable. I, however, do not vouch for the accuracy or the completeness thereof. This material is for personal information and I am not responsible for any loss incurred based upon it.& take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations given in this blog.